Teva Pharmaceutical Industries Ltd
NYSE:TEVA
P/B
Price to Book Value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
Market Cap | P/B | ||||
---|---|---|---|---|---|
IL |
T
|
Teva Pharmaceutical Industries Ltd
NYSE:TEVA
|
66.1B USD | 2.4 | |
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -21 763 099 | |
US |
Eli Lilly and Co
NYSE:LLY
|
733.3B USD | 57.2 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 39.8 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 583.1 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
360.6B USD | 5.2 | ||
US |
Merck & Co Inc
NYSE:MRK
|
329.8B USD | 8.2 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
191.2B GBP | 6.4 | ||
CH |
Roche Holding AG
SIX:ROG
|
177.2B CHF | 6 | ||
CH |
Novartis AG
SIX:NOVN
|
177.1B CHF | 4.9 | ||
US |
Pfizer Inc
NYSE:PFE
|
159.1B USD | 1.8 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.